Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : AS1411
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Qualigen Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Details : Qualigen offers a number of revenue-generating therapeutic and diagnostic products that may help Ritter Pharmaceuticals to advance its pipeline and grow its business.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
April 28, 2020
Lead Product(s) : AS1411
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Qualigen Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : Galacto-Oligosaccharide
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Qualigen Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Ritter Pharmaceuticals, Inc. and Qualigen, Inc. Announce Merger Agreement
Details : The merged company will focus on the development of Qualigen’s nanotechnology therapies for the treatment of cancer and infectious diseases, while also continuing to operate its profitable diagnostic business.
Product Name : Undisclosed
Product Type : Other Large Molecule
Upfront Cash : Undisclosed
January 21, 2020
Lead Product(s) : Galacto-Oligosaccharide
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Qualigen Therapeutics
Deal Size : Undisclosed
Deal Type : Merger
Lead Product(s) : RP-G28
Therapeutic Area : Gastroenterology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
July 24, 2018
Lead Product(s) : RP-G28
Therapeutic Area : Gastroenterology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RP-G28
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
June 20, 2018
Lead Product(s) : RP-G28
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RP-G28
Therapeutic Area : Gastroenterology
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Efficacy, Safety, and Tolerability Study of RP-G28 in Subjects With Lactose Intolerance
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
February 04, 2016
Lead Product(s) : RP-G28
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RP-G28
Therapeutic Area : Gastroenterology
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Inapplicable
April 30, 2010
Lead Product(s) : RP-G28
Therapeutic Area : Gastroenterology
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable